SINOVAC Announces New Board Member
Sinovac Biotech Ltd. (Nasdaq: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the 'Board') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board.
Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School.
Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company's website at www.sinovac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617453752/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
a few seconds ago
What's in Trump's trade agreement with Japan?
President Donald Trump announced a trade agreement with Japan on Tuesday, making it the largest U.S. trade partner to broker an accord as the White House threatens to impose tariffs on dozens of countries within days. Before the deal, Japan faced the prospect of a 25% tariff rate set to take effect Aug. 1. Instead, products from the fifth-largest U.S. trade partner will be slapped with a 15% tariff, in exchange for a willingness on the part of Japan to import some goods, among other concessions. In a post on social media late Tuesday, Trump touted the agreement as a 'massive deal.' The White House has yet to release full details of the agreement. Japanese Prime Minister Shigeru Ishiba also celebrated the accord. 'With the national interests of both countries in mind, we were able to reach an agreement at this time,' Ishiba said. Japan's Nikkei index surged 3.5% on Wednesday, while major U.S. indexes nudged slightly higher in early trading. Here's what to know about what's in the trade agreement and what comes next: What's in the U.S. trade agreement with Japan? The trade agreement lowers the tariff rate on Japanese products to 15%, putting it below the threatened rate of 25% but higher than a universal rate of 10% faced by nearly all imports. Even more, the U.S. agreed to set a 15% tariff on Japanese cars, putting it below the 25% tariff rate placed on imported vehicles from other nations. Japan purchased nearly $80 billion worth of U.S. products in 2024, while the U.S. bought about $148 billion worth of Japanese goods, according to the Office of the U.S. Trade Representative, a government agency. Cars and auto parts accounted for about $52 billion worth of imported Japanese products, making up more than one-third of products purchased by the U.S., government data shows. Shares of Japan-based Toyota soared more than 13% on Wednesday, while Honda jumped about 12%. In exchange for the softening of U.S. tariffs, Japan agreed to open its economy to imports of trucks, rice and other agricultural goods, Trump said. Japan also agreed to invest $550 billion in the U.S. economy, Trump added, but the president did not specify how the funds would be spent. How many trade agreements has the White House achieved so far? When Trump delayed the onset of so-called 'reciprocal tariffs' in April, the White House vowed to strike 90 trade agreements in 90 days. Before that deadline elapsed, Trump proposed a flurry of similar country-specific tariffs with a new effect date of Aug. 1. So far, Trump has brokered agreements with the United Kingdom, Indonesia, Vietnam, the Philippines and Japan. The White House also reached a preliminary accord with China that lowered tit-for-tat tariffs previously imposed by the world's two largest economies. For his part, the president has insisted that the on-again, off-again levies make up a key part of his negotiation strategy. "The president and his trade team want to cut the best deals for the American people and the American worker," White House press secretary Karoline Leavitt said last month when she announced the Aug. 1 deadline. Price hikes could hit coffee, shoes, appliances and a range of other products if additional tariffs take effect on Aug. 1, analysts previously told ABC News.
Yahoo
28 minutes ago
- Yahoo
Jim Cramer on Advanced Micro Devices: 'It's Going in the Right Direction'
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the stocks that Jim Cramer shed light on. A caller asked if Cramer thinks CEO Lisa Su can take the company to a trillion-dollar market cap, and he replied: 'I don't know, but it's going in the right direction. I mean, they obviously have now good GPUs. There's a GPU shortage everywhere. Stock's had a real big run off the bottom. I do think it could have a pullback, but I do think that she's got what it takes to be able to take that stock much higher.' Advanced Micro Devices (NASDAQ:AMD) is a global semiconductor company that designs and supplies microprocessors, graphics cards, chipsets, and embedded processors. On June 9, Cramer remarked: 'So traders say if I can't make money after Broadcom reporting a great quarter, the playbook says time to move into the lower quality, cheaper stocks that are less likely to disappoint or should never have been down to begin with. I understand the sentiment, but the problem is that these stocks have already rallied pretty hard, too…I saw some upgrades for AMD…. They've moved, especially AMD by the way, on speculation it might be involved with any China deal. Rare earth materials for us, AMD chips for them. While we acknowledge the potential of AMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
28 minutes ago
- Yahoo
Texas Instruments Stock Nosedives After Shock Earnings Outlook
July 23 - Texas Instruments (NASDAQ:TXN) shares fell more than 10% in pre-market trading Wednesday after its third-quarter revenue outlook came in below Wall Street estimates, despite delivering stronger-than-expected results for the second quarter. Warning! GuruFocus has detected 11 Warning Signs with TXN. The chipmaker reported Q2 revenue of $4.45 billion, topping the $4.36 billion analyst consensus, and earnings per share of $1.41, also ahead of the expected $1.35. Net income rose 15% year over year to $1.3 billion. Analog chip revenue, the company's core segment, climbed 18% to $3.5 billion, exceeding projections. The growth was driven by demand from the automotive and industrial markets. However, Texas Instruments guided Q3 revenue in the range of $4.45 billion to $4.8 billion, with a midpoint slightly below the $4.59 billion consensus. The company also forecast EPS between $1.36 and $1.60, bracketing analysts' $1.50 average. Shares had been up 15% year to date before the report, helped by broader enthusiasm in the semiconductor sector. The company recently committed $60 billion toward U.S. chip factory expansion, a plan supported by the Trump administration's domestic tech push. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
